VitroScreen Platform

Champions Oncology’s VitroScreen Platform for evaluating therapeutics in an Ex Vivo System

Plate-photo1_croppedIn addition to PDX screens, Champions Oncology has developed a VitroScreen platform in order to screen therapeutic candidates quickly in an ex vivo assay prior to proceeding with a larger in vivo study.

We have developed VitroScreens in various hematological indications, including acute myeloid leukemia (AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), and Mantle Cell Lymphoma (MCL). These screens are enrolled on a quarterly basis and include:

  • A clinically relevant cohort of models used for each hematological indication
  • Primary patient samples that are never passaged in vivo or in vitro in order to maintain clinical relevancy
  • Standard of Care response data and in vitro viability data collected for each model
  • Targeted Truesight Mutation calls and NGS data
  • Full Clinical Characterization 
  • Endpoints include Cell Proliferation, Tumor Cytotoxicity, Apoptosis and/or Phenotyping by Flow Cytometry